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ABSTRACT 
Hereditary nonpolyposis colon cancer (HNPCC) is caused by nlutations in a 
group of genes, A4LIJ L MS'lJ2, MSH6, lv1S113, PMSI and PM.')2, which function in the 
mismatch repair (MMR) pathway. MSH6 nlutations account for approxinlately 11 % of 
disease causing Inutations in HNPCC families, but only a few of these fanli lies fulfill the 
Amsterdanl/Bethesda criteria for patient selection for clinical genetic testing. It is 
difficult to determine the prevalence of MSH6 mutations in the HNPCC patient 
population, since reported lnutation rates vary greatly anlong studies in accordance with 
selection criteria. 'The Inajority of the genetic defects in MMR genes result from point 
Illutations, but genomic rearrangenlents also account for a significant portion, which 
nlight escape detection by using conventional diagnostic techniques. 
To understand the role of MSIJ6 nlutations in North American patients receiving 
HNPCC clinical genetic testing, a consecutive set of 406 samples were nlade anonytnous 
and screened for nlutations in 1\;/SI16, A4LH 1 and MSH2. The spectrum of point 
Inutations versus rearrangements across these genes is also determined by augmenting 
DNA sequencing with MLPA and Southern blot analysis. From using MLPA probe kit 
P008 J\;ISI16/PU~'2 ofMRC-Holland, the deletion of the entire Plvt,,'2 gene was identified 
in a patient with colorectal cancer. 
Sixty-four deleterious lTIutations and 38 genetic variants of uncertain clinical 
signi ficance (VUS) in MLH 1 and AIS}!2 were identified by DNA sequencing in the 
original set of sanlples. Fronl this set. 279 specitnens were subjected to ,\;fSH6 mutation 
testing by DNA sequencing for the entire coding region and consensus splice sequences 
adjacent to the exons. Six protein truncating mutations and 8 missense VUS were 
detected in A4SH6. kILI-J J and A1SH2 Inutations accounted for 89% of total nlutations 
detected in HNPCC in this sample set. Of these mutations, 25% were reanangenlents in 
MLH J and MSH2 detected by Southern blot analysis. MSI16 mutations accounted for 
11 % of total mutations detected in HNPCC in these samples. There were no 
rearrangelnent nlutations detected in A4SH6 by MLPA analysis. Four of the 6 MSH(} 
nluta1ions were identified in sanlples from patients afTected with endometrial cancer. 
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CHAPTER I 
INTRODUCTION 
Hereditary nonpolyposis colon cancer (HNPCC) is an autosomal dOlninant 
condition characterized primarily by increased risk of colon cancer, and cancer of other 
tissues including the endometrium, ovary, stomach, snlall intestine, hepatobiliary tract, 
upper urinary tract, brain, and skin. The average age of diagnosis is the early to mid 40s, 
but tUlnors can emerge in individuals in their early 20s (Baudhuin 2004). HNPCC is one 
of two prevalent hereditary cancer syndromes, the other being familial adenonlatous 
polyposis (F AP), which is caused by mutations in the APC gene. Patients affected with 
HNPCC do not present with large nun-.bers of colonic polyps (sometimes many hundreds 
or even thousands), which occur in FAP. 
Individuals with HNPCC carry an 800/0 lifetime risk for developing colon cancer 
and two-thirds of these cancers arise in the proxin1al colon (Kohlmann and Gruber 2004). 
HNPCC-related colon cancers carry comlnon histopathological features that include 
tUlnor infiltrating lymphocytes, ll1ucin, poor differentiation, signet ring or cribforol 
histology, and the average age of diagnosis is 44 years of age (Kohlmann and Gruber 
2004). The second n10st common cancer in HNPCC individuals is endonletrial canccr. 
Women with HNPCC carry a 20-60% lifetime risk for the development of this cancer 
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(Kohhnann and Gruber 2004). The average age of diagnosis in individuals with HNPCC-
related endometrial cancer is 46 (Kohhnann and Gruber 2004). 
The most frequently reported pathology of HNPCC-related gastric cancers is 
intestinal-type adenocarinoll1a. The mean age of diagnosis is 56 years of age. The 
pathology of HNPCC-related ovarian cancer is analogous to that presented in sporadic 
ovarian cancers. The average age of diagnosis is 42, but 30% of these diagnoses are 
reported before the age of 40. Other HNPCC -related cancers that present with 
characteristic features include urinary tract cancers that are transitional carcinomas of the 
ureter and renal pelvis, also small bowel cancers. A majority of these cancers are 
adenocarcinomas of the duodenum and jejunum. Finally, the most common type of 
central nervous system tumor is glioblastoma is also associated in HNPCC patients. 
Breast cancer, laryngeal cancer, and hematological cancers have also been reported in 
liNPCC families, but a direct association of these cancers to HNPCC has not yet been 
demonstrated (Kohlmann and Gruber 2004). 
Genetics 
HNPCC is caused by mutations in a group of genes that function in the nlismatch 
repair (MMR) pathway: MLII], lvfSH2, MSH3, MSH6, PMS1 and PMS2 (Table 1). The 
role of the proteins encoded by these genes is well characterized in bacteria. The human 
genes show homology with their bacterial counterparts and additional orthologs exist in 
hunlans. The MMR proteins interact to form complexes that identify and repair 






























Adapted from Markwitz S. 2000. DNA repair defects inactivate tumor suppressor genes 




Discovery of MMR Genes and Their Role in HNPCC 
Several HNPCC families meeting the Amsterdam criteria participated in linkage 
studies to define the genomic mapping of associated genes. In May 1993, positive LOD 
scores with DNA markers mapped to chromoson1e 2p was reported in these families 
(Peltomaki et al. 1993). In November 1993, it was shown that there was a linkage to 
chromosome 3p in 3 Swedish HNPCC families (Lindblom et al. 1993). It was later 
shown that a majority of these tumors displayed high microsatellite instability (MSI) that 
was previously studied in bacteria and yeast (Strand et al. 1993) to lead to positional 
cloning strategies identifying the human homologue for the MutS gene (hA1SH2) on 
chromosorne 2p22-21 (Fishel et al. 1993, Leach et al. 1993) followed by the 
identification of the human hOlnologue of the MutL gene (hMLH 1) on chromosome 3p 
(Bronner et ai. 1994, Papadopoulos et al. 1994). 
In the study by Leach et aI., chromosome microdissection was used to obtain 
highly polymorphic markers from chromosome 2p 16. These and other markers were 
ordered in a panel of somatic cell hybrids and used to define a 0.8 Mb interval containing 
the HNPCC locus. Candidate genes were then mapped, and one was found to lie within 
the 0.8 Mb interval that was homologous to MutS mismatch repair genes. cDNA clones 
were obtained and the sequence was used to detect gemtline mutations in A1SH2, 
including those producing termination codons, in HNPCC kindreds. Somatic as well as 
germline mutations of MSH2 were identified in tUlnor cells with high MSI (Leach et al. 
1993 ). 
In the study by Fishel et aI., the expression of hA1SH2 in coli causes a dominant 
mutation phenotype, suggesting that hMSH2 interferes with the normal mismatch repair 
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pathway. A T to C transition mutation was detected in the -6 position of a splice acceptor 
site in sporadic colon tumors and in two small HNPCC kindreds. These data show that S. 
cerevisiae A1SH2 mutations cause instability of dinucleotide repeats like those associated 
with HNPCC to show that MSH2 is one of the genes responsible for HNPCC (Fishel et 
al. 1993). 
hA1Lf-/ 1 ~ hPMSI ~ and hPMS2 were identified by having significant similarity to 
the yeast MulL gene and the yeast MulL homolog PMS'I (Prolla et al. 1994, Kramer et al. 
1989). Somatic cell hybridization studies localized these genes on chromosomes 3, 2. 
and 7 (Papadopoulos et aL 1994). In the study by Papadopoulos et aI., the precise 
chromosomal location of hMLl11 was determined by FISH to locate the gene within band 
3p21.3. The relationship between hMLH 1 and the HNPCC locus was determined by 
physically mapping the region to show the responsible locus is centered at markers 
03S 1611 and D3S 1277. A yeast artificial chromosome (Y AC) clone was identified that 
contained both hJvfLl! 1 and marker 03 S 1611 to show the gene is within 1 eM of the 
HNPCC locus. The derived marker 03S 1611 was found to be located in an intron of 
h~fLlf I. Mutations of hMLH 1 that would disrupt the gene product were found in 
afIected individuals of HNPCC kindreds to reveal that the gene is responsible for the 
disease (Papadopoulos et al. 1994). 
Function of the MMR System 
In E. coli, MutS and MutL proteins are involved in two n1ain repair pathways, the 
methyl-directed long-patch and the very short-patch pathway (VSP). The methyl-
directed pathway corrects base-base mismatches, small insertions and deletions that occur 
during DNA replication (Peltomaki 1997). The VSP pathway functions by correcting G-
T mismatches in nonreplicating DNA resulting from deamination of 5~methlycytosine 
residues (Peltomaki 1997). 
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The initial step of this repair process is the binding of MutS to the mismatch base 
followed by the additional binding of MutL. The formation of this con1plex activates the 
binding of MutH, an endonuclease, which makes an incision at a GATe site with an 
unmethylated adenine located 1 to 2-kb from either side of the n1ismatch (Peltomaki 
1997). The segment containing the n1ismatch is cut by a 3' -5' or 5' 'exonuclease and 
restored with a new segment produced by DNA polymerase (Peltolnaki 1997). In yeast, 
MLEfl and PMSI bind together to form a heterodimer after the detection of the mismatch 
by MSH2, which is followed by the formation ofa ternary complex, lvlLHl, PMSl, and 
MSIJ2, that recruit further proteins to repair mismatches as seen in E. coli (Peltomaki 
1997). 
In humans, it is thought that the MMR system operates in a similar way. Unlike 
E. coli, hUlnan cells have at least 16 genes that specify MutL-like proteins (Peltomaki 
1997). MSH2 and MSH6/MSH3 make up the mismatch-binding factor in humans. MSH2 
proteins bind to DNA containing base-base mismatches and to substrates containing from 
one to 14 extra bases. Several studies of yeast strains containing MSH2, MSfI3, and 
MSH6 n1utatiol1s (Strand et al. 1995, Johnson et al.1996, Marsischky et al. 1996, Greene 
and Jinks-Robertson 1997, Sia et al. 1997) suggest that Jvf.)H2 and MSH6 are mainly 
responsible for repairing base-base 111ismatches. MSH2 can participate with either M5;H6 
or MSf{3 to repair one-and two-base insertion/deletion mismatches. The M'lH2/ AfSH3 
heterodin1er (MutS~) is thought to repair insertion/deletions involving repeating units of 
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Figure 1. Mismatch Repair Mechanism. A mispaired base is recognized by the 
hMSH2/GTBP(MSH6) complex while an insertion/deletion loop is recognized by the 
hMSH2lhMSH3 complex. MutL related proteins (hMLHllhPMS2 and hMLH1 IhPMS 1 
complexes) then interact with the MutS related proteins that are already bound to the 
mispaired bases. 
Reprinted by permission of Wheeler J, Bodmer W, McC Mortensen N. 2000. DNA 
mismatch repair genes and colorectal cancer. Gut 47:148-153. 
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proteins, a heterodimeric complex of the MutL related proteins (A1LHlIPAlSl, PA4S2 in 
humans) interacts with the AlutS related proteins bound to the misnlatches (Prolla et al. 
1994, Li et al. 1995). MLH 1/ P MS 1 binds to the A4SH2/ MSH 3 mismatched conlplex to 
increase the efficiency of MutS related proteins to recognize a n1isnlatch (Habraken et al. 
1997). MLH 1 also forms a conlplex with P MS2 to playa role in the repair of 
insertion/deletion mispairs in the M)H2/ M)H3 pathway (Flores-Rozas et al. 1998)_ 
MLH 1 protein also dimerizes with PMS2 to direct the binding of other proteins including 
l:XO 1, helicases, proliferating cell nuclear antigen (PCN A), single-stranded DNA-
binding protein (RPA), and DNA polymerase (Kohlmann and Gruber 2004). 
There are additional proteins involved in mismatch repair that include DNA 
polymerase 8, replication protein A, proliferating cell nuclear antigen (PCNA), 
replication factor C, exonuclease L FENL and DNA polymerase 8 and B associated 
exonuc1eases (Syngal et al. 1999). The "clamp" protein, PCNA, is required to stabilize 
the AI/utS and NfutL heterodimers at mismatch sites and during the DNA synthesis step of 
tnismatch repair. After the nlisnlatch is recognized and the complexes have formed, the 
degradation of the mismatch bases is removed by exonuclease (with assistance fron1 
helicase II and SSB proteins) that is initiated from a nick located 1 kilobases from the 
mismatch bases. The resulting excision tract is restored by DNA polymerase. 
It may seem that MSH2 and MLHI play equal roles in the repair of single base 
misn1atches, but A1S'H2 plays a larger role in the repair of loops of five or lnore unpaired 
bases (PeltOlnaki 1997)_ Hunlan cells have the ability to repair large loops, which is 
important because human DNA contains a lot of microsatellites that may produce these 
loops (Peltomaki 1997). 
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There might be some redundancy in the functions of the MSH2-MSH3 and 
MSH2-MSH6 heterodimers. This redundancy could explain the reduced severity of 
MSH6 mutations that are believed to be associated with lower penetrance and later age of 
onset when compared with mutations in lWLHl or MSH2. It is possible that loss of !vISH6 
function is mitigated by MSH3 in the repair of one- and two-base insertion/deletion 
mismatches. 
The Prevalence of Mutations in MMR Genes in HNPCC 
While all MMR genes could playa potential role in hereditary risk for colon 
cancer, most germline mutations identified to date occur in MLHl on chromosome 
3p22.3 and MSfl2 on chromosome 2p21 (80-90%) (Kohlmann and Gruber 2006). 
Mutations in additional genes involved in MMR, MSH6 on ChrOlTIOSOme 2p 16.3, MS}!3 
on chromosome 5q14.1 and PMSl and PMS2 on ChrOlTIOSOme 2q32.2 and 7q22.1, are 
associated with HNPCC, but probably play lesser roles that are defined through ongoing 
research studies (Hedge et al. 2005). 
PA1S2 mutations are rare and have been reported in a few fanlilies \\lith cancer 
(Nicolaides et at. 1994, Hamilton et al. 1995, Miyaki et al. 1997, De Rosa et at. 2000, 
Trimbath et al. 2001), including the identification of four rearrangements in PlvtS2 (van 
der Klift et al. 2005). It has been shown that P!viS2-mutated hun1an cells display a 
mutation rate equivalent to or more than that ofMLfll-mutated human cells (De Vos et 
al. 2004). The existence of several pseudo genes corresponding to the first five exons, 
exon 9 and exons 11-15 of P MS2 could interfere with mutation detection resulting in 
under diagnosis (De Vos et al. 2004, Nakagawa et al. 2004). 
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The mechanism through which PM)2 mutations confer susceptibility to HNPCC-
related cancers is still unknown. It has been suggested from recent studies that P MS2 
plays a more important role in rlNPCC than previously thought in which the MutLa 
heterodimer formed by MLH 1 and PA4S2 proteins is a major component of the MMR 
complex (Nakagawa et a1. 2004). 
Pseudogenes and P M)2 
Pseudogenes are a faulty segment of DNA that resembles a known functional 
gene that have lost their protein-coding ability or are no longer expressed in the cell 
(pseudogene.org 2007). The tirst pseudogene was reported in 1977 (Jacq et a1. 1977). 
Since that time most of these pseudogenes have been discovered in humans and other 
species (PittTIan 2004). Three main types of pseudogenes exist, each with distinct 
mechanisms of origin and distinct characteristic features. 
Nonprocessed or duplication pseudogenes are the first classification of 
pseuodgenes. These genes occur by tTIodification to the DNA sequence of a gene during 
duplication by mutations, insertions, deletions or frameshifts to resuh in loss of gene 
function at the transcription or translation level (Figure 2) (Pseudogene.org 2007). 
Duplicated pseudo genes usually have all the same characteristics of functional genes, 
including an intact exon-intron structure and promoter sequences (Pseudo gene 2007). 
The loss of the duplicated gene's function usually has little effect on the organisnl, since 
an intact functional copy still exists. Exan1ples of nonprocessed pseudogenes are present 

























Figure 2. Mechanistn of Processed and Duplication Pseudo gene Occurrence 
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Reprinted by permission of Harrison P, and Gerstein M. 2002. Studying genolnes through 
the aeons: protein families, pseudogens and protein evolution. Journal of Molecular 
Biology 318: 1155-74. 
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Processed pseudo genes are the second classification of pseudogenes. These genes 
arise by reverse transcription of an mRNA transcript followed by reintegration of the 
cDNA into the genome (Pseudogene.org 2007). They are called "processed" because 
these genes have been spliced and lack introns (Gibson 1994). These genes often have 
poly (A) tails at their 3'-end, lack promoter sequences and are flanked by short direct 
repeats. The L 1 family of repetitive DNA sequences appears to be the result of this 
process (Jurka 1989). 
Disabled genes or unitary pseudogenes are the third classification of pseudogenes. 
These genes arise by the same mechanism by which nonprocessed genes become 
deactivated, but the only ditTerence is that these genes \vere not duplicated before 
becoming disabled (Wikipedia 2007). 
A novel PUS2 related gene \\'as identified in chromosome 7p22-23. The gene 
contains an identical sequence (97%) to exon 9 and exons 11-15 ofPMS2 (Nakagawa et 
a1. 2004). It was shown by Western Blot that the transcript is not translated into a 
protein, which could be due to a 2-bp deletion and 1-bp insertion in the exon 
corresponding to exon 11 of PM",'2 (Nakagawa et a1. 2004). Other paralogous sequences 
(at least 13) resemble the 5'end of PMS2 that extend over exons 1-5 (Nakagawa et al. 
2004). 
Microsatellite Instability in HNPCC 
Mutations in MLHI and MSH2 are associated with a tumor phenotype exhibiting 
increased genomic instability, characterized by changes in repeat numbers of simple 
repetitive sequences also referred to as rnicrosatellite instability (ivISI). Microsatellites 
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are regions of DNA (I-S base pairs, usually repeated IS-30 times) with a repetitive 
sequence of nucleotides (Jover et al. 2004), which are susceptible to errors during DNA 
replication that relnain non repaired in MMR defective cells. Approximately 100,000 
microsatellite repeats spread throughout the hUlnan genolne (Peltomaki 1997) are 
susceptible to insertions or deletions. A group of two mononucleotides markers, BAT2S 
and BAT26 and three dinucleotide repeat markers, D2S123, DSS346, and D17S2S0, has 
been recommended by the National Cancer Institute to determine MSI in tumor and 
normal tissues (Umar et al. 2004). A tumor is classified as MSI-high if two or more of 
the microsatellite markers show instability and is classified as MSI-iow if one of the 
microsatellite markers shows instability (Jagadeesh et al. 2003). 
About 900/0 of familial colon cancers that meet the Amsterdam Criteria are MSI-
high (Kohlmann and Gruber 2006). Mutation rates in these repetitive sequences are 
about 100 times greater in mutated MLH 1 and AISl!2 cells compared with MMR 
proficient cells (Chao et al. 2006). Most of the MLHI and MSH2 mutations cause MSI-
high tumors, but A;fSH6 mutations can display an MSI-iow phenotype. Functional 
redundancy in the DNA nlismatch repair pathway could explain the MSI-iow phenotype 
of MSH6 mutations when compared with ~fLH 1 and MSH2 (Buttin et al. 2004). 
Genonlic Rearrangements 
The lnajority of the genetic defects in MMR genes result fronl point mutations~ 
but genomic rearrangements also account for a significant portion of mutations in 
HNPCC (van der Klift et al. 200S). Rearrangement mutations are especially prevalent in 
MSH2. It has been shown that rearrangement mutations account for about 30-50% of 
lUSH2 mutations in HNPCC (Ball et al. 2003). These rearrangenlents fail detection in 
conventional PCR-based methods, such as Denaturing High Performance Liquid 
ChrOlnatography (DHPLC), Single Strand Conformation Polymorphism (SSCP), and 
direct DNA sequencing, that are eflective at finding single-base substitutions, small 
deletions and insertions, but are insensitive to large gene reanangement detection. 
Mechanisms of Rearrangements 
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Four general mechanisms of rearrangements are found in DNA~ replication 
slippage, intrachromosomal crossover event, single strand annealing, and unequal 
crossing over between sister chromatids. In the first nlechanism, replication slippage, 
DNA polymerase detaches from the DNA strand and reanneals to nearby homologous 
sequences to result in small deletions or insertions usually seen in microsatellite regions 
(Figure 3). 
There are two nlechanisms that results in intrachromosomal deletions. In the first 
mechanism, intrachromosomal crossover event, homologous sequences are aligned then 
followed by a break in a single strand to allow strand exchange and reconlbination 
between the two honlologous sequences. In the second mechanism, single strand 
annealing, a double strand break forms in a nonhomologous segment between repeats or 
within a single repeat element (Figure 4). In the double strand break, DNA degradation 
of the single strands from the 5' exposed ends occurs to result in single stranded 
segments that anneal to each other followed by processing of the 3' tails and ligation of 
the nicks to produce the deletions. 
The final mechanism results in interchronl0somal rearrangements. This incident 
is mediated by unequal crossing over between nlisaligned homologous segments on 
homologous chromosomes or sister chromatids resulting in two reciprocal chromosomal 
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Figure 3. Mutations Caused by Replication Slippage (a) Nonnal replication. (b) 
Backward slippage, resulting in the insertion mutation. (c) Forward slippage, resulting in 
the deletion mutation 
Reprinted by permission of Molecular Biology Web Book. (2006). <http://www.web-
books.com/MoBio/Free/Ch7F3.htm>. Accessed 2007 Sept 18. 
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Figure 4. Single-Strand Annealing Model. When a double-strand break is created in 
vivo, one strand on each side of the DSB is resected in the 5'-to-3' direction, leaving a 3' 
tail. When complementary sequences on opposite sides are exposed, they can anneal, 
forming a branched intermediate. The single-stranded tails are removed by a nuclease, the 
gaps are filled in, and any remaining nicks are ligated, resulting in a deletion product. 
Reprinted by permission of Sugawara N, Ira G, Haber J. 2000. DNA length dependence 
of the single-strand annealing pathway and the role of Saccharomyces cerevisiae RAD59 
in double-stand break repair. Molecular and Cellular Biology 20(14):5300-5309. 
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(a) 
Centromere Repeat unit 
(b) 
(c) 
Figure 5. Unequal Crossover and Sister Chromatid Exchange. (a) T\\lO pairs of sister 
chromatids line up during meiosis. A repetitive region of one chromatid does not line up 
exactly with its corresponding region in other chromatids. 
(b) Strand breaks on nonsister chromatids (along line A) will result in unequal crossover, 
producing difTerent number of repeat units in these chronlatids. 
(c) Strand breaks on sister chrOlnatids (along line B) also produce difTerent repeats. In 
this case, it is called sister chrornatid exchange. 
Reprinted by pernlission of Molecular Biology Web Book. 2006. <http://www.web-
books.com/MoBio/Free/Ch8D6.htm>. Accessed 2007 Sept 18. 
products: one contains a duplication of the region located between the two sites and the 
other contains a duplication of the region located between the two sites and the other 
contains a deletion that covers the sanle exact region (Figure 5). The size of the 
duplicated region can vary from a few base pairs to tens or even hundreds of kilobases. 
Rearrangement Detection Methods 
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Gene rearrangements have been detected by many methods including Fluorescent 
In Situ Hybridization (FISH), Southern blot analysis, and peR amplification assays. The 
principle of FISH assay is the hybridization of fluorescent probes to denatured 
conlplementary target DNA. The hybridized sequences are observed by fluorescent 
microscopy. It is one of the methods used in the detection of large rearrangenlents 
(Honda et al. 2000, Elcioglu et aL 2000). Three cryptic and one complex BeRf ABL 1 
rearrangenlents were detected by FISH assay, which 'were not visible by conventional 
cytogenetics (Pelz et al. 2002). 
Southern blot assay is another method used to detect large rearrangements 
(Nordling et al. 1998, Puget et al. 1997, Swensen et al. 1997). The DNA is digested with 
a restrictive enzyme and separated by gel electrophoresis. The DNA is denatured by 
NaOH and transferred to nitrocellulose or nylon membrane. The blot is incubated with 
many copies of a labeled probe to hybridize to the complementary DNA sequence. The 
pattern of hybridization is visualized by autoradiography or by non-radioactive 
visualization by colorimetric, fluorescent, or chemiluminescent detection of the probes. 
The probe reveals the fragnlents that contain the target DNA sequence and can be 
mapped back to the genomic sequence and region where the deletion or duplication 
occurred. 
Forty-eight genomic rearrangements in the MMR genes were identified in a 
cohort of 439 HNPCC families by Southern blot analysis (van der Klift et al. 2005). 
Twenty-nine of these mutations were found in MSH2 , 13 in MLH2, 2 in MSH6 and 4 in 
PMS2. In another study, a 2.1-kb deletion of exon 1 in MSH2, along with a 5.4-kb 
deletion of exon 2, a 2.2-kb deletion of exon 3, and a 13-kb deletion of exon 6 was 
identified by Southern blot analysis (Wijnen et al. 1998). 
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PCR-based amplification assays have also been used for the identification of 
rearrangements. These assays are rapid and versatile in vitro methods for amplifying 
defined target DNA sequences within a source of DNA. One successful assay for the 
detection of rearrangements is long range PCR. This method involves the use of two 
polyn1erases, a nonproofreading polymerase and a proofreading polymerase with 3' to 5' 
exonuclease activity to remove n1ismatched bases to achieve the amplification of large 
DNA fragments. PCR amplification will produce a smaller fragment than the wildtype 
DNA if a deletion is present or a larger fragment than the \vild type if a duplication is 
present. The deletion of the promoter region of exon 1 and exon 2 in MSH6 and the 
duplication of the 3' end of exon 4 and exon 5 in MSH6 was detected and characterized 
by long range PCR and DNA sequencing (Plaschke et al. 2003). In another study, 
thirteen different genomic rearrangements of MSH2 were confirmed and characterized by 
long range PCR (Carbonnier et al. 2002). 
Southern blotting, the most commonly used procedure to detect genomic deletions 
and duplications, is offered by a majority of laboratories performing clinical testing for 
HNPCC patients. However, this technique suffers fron1 major limitations that include the 
requirement of large amounts of DNA, the need for expert analysis and is time 
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consuming and laborious. Solutions to these problems have been proposed in the form of 
assays that detect rearrangement mutations by quantitative PCR. 
One assay in particular, multiplex ligation probe amplification (MLPA), is 
gaining rapid adoption since it has all of the advantages of the PCR-based assays using a 
single PCR primer set to increase PCR inefticiencies, and is available as a commercial 
kit. MLPA is a new technique that allows the quantiiication of multiple nucleic acid 
sequences in one reaction tube (www.mlpa.com).TnMPLA.amixture of different sized 
probes are added to the samples and allowed to hybridize overnight to adjacent target 
sequences then amplified by PCR and quantified. Amplified products are separated by 
electrophoresis in which the relative amounts of probe amplification products are 
proportional to the relative copy number of the target sequence. 
Thirty-eight germline mutations were detected in 37 of the 126 colorectal cancer 
families by MLPA. Thirteen genomic deletions were identified in lvlSH2 and 4 in 
lvlLHi, including the deletion of the entire MLHi gene detected in two families (Gille et 
a1. 2002). In another study, 12 cases with deletions of one or more exons, six deletions in 
MLHi and six deletions in 11'!/;;H2 were identified by MLPA (Taylor et a1. 2003). 
Genetic Testing 
Patient Selection by Family History 
Genetic testing for mutations in the genes that cause these cancer syndromes 
improves patient lnanagement. Currently, genetic testing for both HNPCC and FAP is 
used primarily to coniirm diagnoses. Confirmed mutation carriers affected with cancer 
receive recommendations for more aggressive surgery (American Gastroenterology 
Association 2003). Unaffected mutation carriers are recommended to undergo increased 
cancer surveillance by colonoscopy every 1-2 years (American Gastroenterology 
Association 2003). Patients that do not carry a known familial mutation can receive 
surveillance appropriate for the general population. These patients can forgo yearly 
colonoscopy procedures that are uncomfortable and expensive (American 
Gastroenterology Association 2003). 
Amsterdam Criteria 
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Genetic testing for HNPCC involves complex and expensive "Thole-gene 
mutation scanning and thus is inappropriate for screening the general population. 
Presently, the most important criteria for selecting patients for clinical genetic testing are 
based upon family cancer history. In 1990, the International Collaborative Group on 
HNPCC established the Anlsterdam Criteria to identify HNPCC families for research 
studies. These criteria include three or more family members (one men1ber \vho is a tirst 
degree relative of the other two) with a confirmed diagnosis of colorectal cancer or 
HNPCC-related cancers, two successive affected generations, one or more colorectal 
cancers or HNPCC-related cancers diagnosed under 50 years of age, and the exclusion of 
FAP (Kohlmann and Gruber 2004). These criteria were later modified in the Amsterdam 
II Criteria to include other HNPCC-related cancers and to recommend that the tU1110rs are 
verified by a pathological eXaJllination (Figure 6), 
In 1997 ~ the Bethesda guidelines were forrrlulated to expand the identification of 
MMR gene l11utation carriers (Berends 2003). These criteria include individuals with 
colorectal cancer family history that meet the Amsterdam criteria, individuals 45 years 
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I Amsterdam I Criteria 
• Three or more relatives diagnosed with colorectal cancer, 1 of whom is a first 
degree relative of the other 2 
• Colorectal cancer involving at least 2 
generations 
• One or more colorectal cancer diagnosed at 50 years or older 
I Amsterdam II Criteria I 
• Three or more relatives diagnosed with HNPCC related cancers, 1 of whom 
is a first degree relative of the other 2 
• Colorectal cancer involving at least 2 
generations 
• One or more colorectal cancer diagnosed at 50 years or older 
I Modified Bethesda Criteria I 
• Individuals in families that meet Amsterdam criteria 
• Individuals with 2 HNPCC-related cancers including synchronous and 
metachronous colorectal cancers or associated extracolonic cancers 
• Individuals with colorectal cancer and a first degree relative with colorectal 
cancer and/or HNPCC-related extracolonic cancer and/or colorectal 
adenoma; 1 of the cancers diagnosed at age< 50 years and the adenoma 
diagnosed at age <40 years 
• Individuals with colorectal cancer and endometrial cancer diagnosed at age 
< 50 years 
• Individuals with right sided colorectal cancer with an undifferentiated pattern 
on histology diagnosed at age <50 years 
• Individuals with signet ring cell type colorectal cancer diagnosed at age 
<50 years 
• Individuals with adenomas diagnosed at age <40 
years 
Figure 6. Summary of Diagnostic Criteria for Hereditary Nonpolyposis Colorectal 
Cancer 
Adapted from Jagadeesh D., Syngal S. 2003. Genetic testing for hereditary 
nonpolyposis colorectal cancer. Current Opinion in Gastroenterology 19(1 ):57 -63. 
23 
old or younger with colorectal cancer, or 45 years old or younger with endometrial 
cancer, or 40 years old or younger with a colorectal adenoma, individuals with colorectal 
cancer and a first-degree relative with colorectal cancer or an HNPCC-related cancer, 45 
years or younger with one of the cancer diagnosed or HNPCC-related cancers and 
individuals with two HNPCC-related cancers, including synchronous and metachronous 
colorectal cancer. 
These guidelines were later revised stating that patients need to meet one of these 
criteria: diagnosed with colorectal cancer before the age of 50 years, colorectal cancer 
with a high MSI morphology that was diagnosed before the age of 60 years, colorectal 
cancer with one or more first-degree relative with colorectal cancer or other HNPCC-
related tumors that was diagnosed before the age of 40 years and colorectal cancer with 
two or more relatives with colorectal cancer or other HNPCC-related tumors regardless 
of age (Recognizing Hereditary Cancer 2006). 
Patient Selection by Molecular Tumor Analysis 
A second approach for identifying candidates for mutation screening involves the 
molecular analysis of tumors. Colon tumor tissues can be screened by a combination of 
PCR-based assays to assess MSI and immunohistochemical (lHC) analysis to determine 
the loss of particular MMR proteins. The gene corresponding to the lost protein is 
screened by molecular assays using DNA from a blood sample to determine the 
underlying gern1line mutation. 
The approach of using the prescreened tumors to identify MMR genes for 
subsequent mutation scanning is incorporated into guidelines prepared by the American 
Gastroenterology Association (http://www.gastro.org/). The recommended initial test is a 
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combination of MSI and IHC analysis for MSHl and MSH2 mutations in individuals 
fulfilling the Amsterdam criteria, the revised Bethesda criteria and in first degree adult 
relatives of mutation carriers (Umar et al. 2004). If a MSI-high tUlnor is detected then 
germline testing is performed by DNA sequencing, conformational sensitive gel 
electrophoresis (CSGE) or single-strand conformational polymorphism (SSCP) for 
mutations in MSlf 1 and MSfl2 (Umar et al. 2004). IHC is a fast and reliable screening 
tool for mutation detection in HNPCC individuals. IHC was successful in detecting the 
loss of MSH6 antibody expression in 20 of 23 cases that carried underlying MSfl6 
mutations (Plaschke et al. 2004) 
Molecular Techniques and Mutation Spectrum 
Clinical molecular genetic testing for HNPCC is an evolving field that is being 
driven by requirements for increased sensitivity for mutation detection. Initially, clinical 
offerings were limited to point mutation and small insertion/deletion screening in MLH 1 
and MSlI2. A variety of techniques were employed tor mutation detection including: 
DDGE, DHPLC, Single Strand Conformation Polymorphism (SSCP), and direct DNA 
sequencing (Gille 2002). In the United States, direct DNA sequencing has become the 
predominate method for clinical testing due to high analytical sensitivity. 
These PCR-based methods are effective at finding single-base substitutions, small 
deletions and insertions, but are insensitive to large gene rearrangement mutations, such 
as genomic deletions or duplications that impact prin1er annealing sites. When a 
rearrangement mutation disrupts an amplicon, the mutation remains undetected since 
only the signal from the normal allele is analyzed. Discoveries of rearrangement 
mutations in MLHI and A1SH2, where up to one-third of mutations can be 
rearrangements, have prompted the incorporation of assays to detect these mutations in 
clinical tests. 
Multiplex Ligation Probe Amplification Analysis 
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MLP A is rapidly being adopted by clinical laboratories for rearrangement 
n1utation detection. In MPLA, multiple loci can be screened for rearrangement l11utations 
by highly multiplex PeR-based target dosage analysis. The technique is rapid, cost-
efTective and consun1es minimal sample. The application of this novel method is being 
facilitated by the commercial availability of assay kits for an increasing set of genes and 
applications including BRCA1, BRCA2, MLH1, MSH2, MSH6, and PMS2. 
In MPLA, a mixture of different sized probes are added to the samples and 
allowed to hybridize overnight to adjacent target sequences then amplified by peR and 
quantified (Figure 7). Amplified products are separated by electrophoresis in which the 
relative amounts of probe amplification products are proportional to the relative copy 
number of the target sequence. 
Each probe is made up of two oligonucleotides, one synthetic and one M 13 
derived, that hybridizes to sites adjacent to the target sequence. The short synthetic 
oligonucleotide of each probe contains a target-specific sequence of 21-30 nucleotides 
(nt) at the 3' end and a common 19 nt sequence that is identical to the labeled peR 
primer at the 5' end. The long MLPA probe contains a target-specific sequence of25-43 
nucleotides that is cloned into one of the M I3-derived SALSA vectors. These tailed 
probes are I igated so that they n1ay serve as targets in peR using a single primer pair. 
In the study by Taylor et al. (2003), 12 rearrangements were detected in 1'vL)/12 
and MLH 1, in addition to the detection of 13 previously unreported point mutations and 
MLPA, Multiplex Ligation-dependent Probe Amplification 
Denatured genomic DNA is hybridized with a mixture of 40 probes. 
Each MLPA probe consists of two oligonucleotides, one synthetic 
one M13-derived. 




t peR primer sequence X 




Each M13 derived probe 
oligonucleotide has a 
different stuffer sequence. 
The two parts of each 
probe hybridise to 
adjacent target 
sequences 
The two parts of 
hybridised probes are 
ligated by a thermostable 
ligase. 





X The amplification product of 
each probe has a unique 
3' length (130-480 b P ). 
Ampli'fication products are separated by electrophoresis. Relative amounts of 
probe amplification products reflect the relative copy number of target sequences. 
Figure 7. Outline of the MLPA Reaction 
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Reprint by permission of Schouten J, McElgunn C, Waaijer R., Zwijnenburg D, Diepvens 
F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex 
ligation-dependent probe amplification. Nucleic Acids Research 30: e58. 
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16 point mutations already in the literature. Overall detection sensitivity was increased 
by 50% and test failures were less than 5% mainly due to low DNA volumes. Gille et al. 
(2002) detected 16 genomic deletions in 126 Dutch fanlilies to also denlonstrate that 
MLPA is a cost effective and robust gene dosage method that can readily be integrated by 
diagnostic services. 
The method is rapid and ready-made commercial kits are available for many 
genes. The l-INPCC ML,PA assay checks the dosage of 35 exons against seven control 
amplicons in a single reaction tube. Washing to relnove the nonhybridizing hemi-probes 
is not necessary since the probes will not be ligated and amplified. Data review is rapid 
and robust by the use of fonnatted spreadsheets or by software analysis, such as 
GeneMarker (SoftGenetics, State College, PA) or Genotyper (Applied Biosystenls). 
There are also some disadvantages of using MLPA in the detection of genomic 
rearrangements. First, the use of M 13 (single stranded) probes are technically 
challenging to construct if not included in the commercial kits. Second, polymorphisms 
or single base mutations in the probe binding regions may affect MLPA results. 
Nucleotide nlisnlatches at and near the probe binding site may prevent hybridization and 
I igation to appear as exon deletions. It is recolnmended that any small fragment 
deletions, namely single exon deletions, detected by MLPA should be confirmed by 
another method. MLP A is also very sensitive to DNA quality and should only be used 
with DNA from the sanle extraction method as per the manufacturer's instructions. 
SALSA MLPA Kit P0081vlSH61PMS2 
The SALSA MLPA kit P008 MSH61 PA1S2 provides a sinlple and fast method to 
detect deletions of one or nl0re exons of MSH6 and P M)2. The kit contains MLPA 
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probes for each of the 10 MS,~H6 exons and probes for 13 of the 15 PMS2 exons as well as 
a tew probes (3-5) for MLI!l, MLH3, MSH2, MSH3, and NfYH. Details of probe 
sequences can be found on http://www.mrc-holland.com. Some PM)2 probes contain 
identical sequences to one or more P MS2 pseudogenes so some P !-vIS2 probes have been 
placed in introns. DNA quality (DQ) control fragments are included in each SALSA 
probe mix. The DQ fragments provide amplification products that are shorter than the 
probe amplification products. This provides a warning when not enough DNA was used 
to obtain reliable results or if the ligation reaction failed. 
MSH6 Mutations in HNPCC 
According to the database of the International Collaborative Group on HNPCC, 
MSH6 mutations account for approximately 10% of all the detectable disease causing 
mutations in HNPCC families (Peterlongo et a1. 2003). Only a few of these mutations are 
reported from families that tit the Amsterdam criteria or in tumors with an MSI-high 
phenotype (Peterlongo et a1. 2003). Up to 39% of families with mutations in an HNPCC 
gene do not meet the Amsterdam Criteria (Syngal et a1. 2000), ·which is especially seen in 
MSH6. 
The Prevalence of MSl!6 Mutations in HNPCC 
From other studies, it has been shown that it is difficult to determine the 
importance of MSf!6 n1utations in HNPCC, since the reported prevalence varies greatly 
an10ng studies in accordance with selection criteria of patients for research studies 
(Hendrickson et a1. 2005). It has been suggested that germline mutations in AlSfl6 are 
more evident in people with a later age of onset of colorectal cancer whose tumors 
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display a MSI-Iow phenotype (Peterlongo et al. 2003). The redundancy of function in the 
DNA MMR system, specifically MutS, could explain the MS-stability in tumors of 1\4S1f6 
germline mutation carriers when compared with MSH2 and MLHl (Buttin 2004). MSH6 
kindreds are often characterized by endometrial cancers, lower penetrance of colorectal 
cancer. and later age of onset when cOlnpared with kindred that carry MLH 1 and MSH2 
mutations. It has been reported by many authors that 52-73% of cancers in M5;H6 
gernlline mutation carriers are endometrial cancers (Buttin et al. 2004). 
Kolodner et al. identified lvLSH6 nlutations in families who did not fulfill the 
Amsterdam and Bethesda criteria, with the average age of diagnosis of 61 years of age. 
Plaschke et al. reinforce the limitations of the classical criteria for MSH6 detection in 
HNPCC individuals, reporting that two-thirds of families carrying MS]-!6 mutations 
would have not been detected by using the both the classical or revised Amsterdam 
criteria. Since the MSI phenotype is variable in MSH6 mutation carriers or family history 
may fail to identify MSH6 mutations, it is suggested that screening for A15;H6 mutations 
should be performed when testing is negative for MSH2 and A1LH 1 germline mutations. 
It may be unreliable to only use MSI for the initial screening ofMSl!6 mutations due to 
the MSI-Iow phenotype in these tumors. 
Genomic Rearrangements in iVfSH6 
Genomic rearrangements in MSH6 playa lesser role in the spectrum of nlutations 
causing HNPCC when compared to mutations in lvfLH 1 and MSH2. It has been shown 
that 10-20% of patients with MSH6 negative tumors carry germline rearrangements in 
this gene (Plaschke et al. 2003). Three patients of 15 who tested negative for MMR 
nlutations and displayed tumors with loss of MSH6 protein expression were analyzed 
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using peR-based relative quantification of MSH6 fragments (Plaschke et al. 2003). A 
duplication of the 3' end of exon 4 and exon 5 and a deletion of the functional promoter 
region and the first two coding exons from one allele of the MSlf6 gene were identified in 
2 of the 3 patients (Plaschke et al. 2003). These patients fulfilled the Bethesda guidelines 
and the tumors were classified as MSI-high (Plaschke et al. 200J). 
CHAPTER II 
OBJECTIVES OF THIS STUDY 
The purpose of this study is to determine the role of MSH6 mutations in North 
American patients receiving clinical genetic testing for HNPCC. The relative prevalence 
of mutations in MLHl, MSH2, and MSH6 in these patients was also determined in this 
study. By augmenting direct DNA sequencing with rearrangement detection by Southern 
blot analysis and by MLPA, the spectrum of point mutations versus rearrangements 
across these genes was also determined. Any clinical benefits (increased sensitivity) 
from pooling these tests together will also be demonstrated along with any clinical 
characteristics, such as tissue preferences, of genetic mutations among HNPCC 
individuals. 
CHAPTER In 
MATERIALS AND METHODS 
Patient Sample Selection 
The set of 406 specimens were Inade completely anonymous, while information 
regarding mutation status and some aspects of family history were retained, were 
previously subjected to clinical genetic testing for HNPCC by direct sequencing of the 
coding and flanking splice acceptor/donor regions for MLHl and MSH2 genes. Southern 
blot analysis of MLH 1 and MSH2 for rearrangement mutations was also performed. 
Sixty-four deleterious mutations and 38 genetic variants of uncertain clinical significance 
in MLH 1 and MSH2 were identified by DNA sequencing in this sample set. Two 
hundred seventy-nine samples contained adequate material for MSH6 mutation 
prevalence testing by DNA sequencing and MLPA analysis. The samples were grouped 
into six categories based on cancer frequency reported fronl patients and their family 
history (Table 2). 
MSH6 Testing 
Nucleotide Sequencing 
The prevalence of M5.,~H6 nlutations was determined by direct sequencing for the 
entire coding regions and splice acceptor (20 bps upstream) and donor sites (10 bps 
downstream) next to the exons. Several design elements were integrated into the assay to 
Table 2 





















Patient samples were grouped into six groups based on cancer frequency of endon1etrial 
cancer (EC) and colorectal cancer (CRC) reported from patients and their families 
(Hendrickson et al 2005) 
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achieve optimal sensitivity. PCR buffers designed for G-C rich regions, such as in the 
promoter, were utilized instead of using a standard PCR buffer during PCR (PCRx 
Enhancer System, Invitrogen, Carlsbad, CA.) Prinlers were designed to avoid 
commonpolymorphisms surrounding the exons by sequencing a genetically diverse set of 
96 DNAs that were defined by SNP haplotypes to identify these polymorphisms. Dye-
primer chemistry (Big Dye, Applied Biosystems, Foster City, CA) was used for 
nucleotide sequencing and the sequence was screened for both the forward and reverse 
strands. 
A comlnercially available program (Mutation Surveyor, SoftGenetics, State 
College, PA) \vas used for data analysis of direct sequencing results, which was validated 
in the laboratory by correctly identifying 50 known variants in 240 sequencing 
chromatograms. Visual confirmation was performed for all MSH6 mutations identified 
by the software. 
MLP A Analysis 
The 279 samples negative for MIl-I] and MSlf2 Inutations were subjected to 
MLP A analysis for the detection of MSH6 rearrangement mutations. MLP A was 
conducted according to the manufacturer's protocol using the MLPA probe kit P008 
MSH6IPA,fS2 ofMRC-Holland (http://w\vw.mrc-holland.com). DNA samples (20-
SOOng) were diluted with water to SuI and then heated at 98° C for 5 minutes in a 96 well 
thermocycler with a heated lid. After cooling to 25° C, the DN A was mixed with the 
probe set and high salt butTer (MLPA butTer). The mixture was re-·heated to 95° C for 1 
minute and then incubated at 60° C for 16 hours. DNA ligase and ligation buffer were 
added following probe hybridization, which was incubated at 54°C for 10-15 minutes. 
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The ligation products were next amplified by PCR using the following PCR conditions: 
30 seconds C~ 30 seconds 60°C; 60 seconds 72° C for 33 cycles and followed by end 
incubation at 72° C for 20 minutes. Fragment analysis was en1ployed on automated 
capillary electrophoresis instruments (MegaBACE 1000, GE Healthcare, Chalfont St. 
Giles, United Kingdom) using ROX-550 (Bioventures, Inc) as size standard. 
Data analysis. Data analysis was performed by examination of the capillary 
electrophoresis peak profiles using GeneMarker software (Softgenetics, Inc). Data 
normalization is first performed to increase the low intensities of larger fragments due to 
low efficiency of PCR reactions and low injection rates during electrophoresis. Data 
norn1alization is performed by taking the square root of the intensity ratios then plots the 
ratios to model a linear regression, using the control probes as reference points. The 
exponential function, a*e-bz, is used to fit the square root of peak intensities, where z is 
size, and a and b are fitting constants. 
After intensity normalization, the data are plotted into two formats, ratio and 
regression analysis. Both MLPA analysis methods identify data points as outliers by the 
taking deviation of each allele peak relative to the average deviation of all peaks. If an 
individual peak whose residual deviation is higher than three+ times the average 
deviation then it is defined as an outlier. 
In MLP A ratio analysis, the intensity ratios of the same probes from the patient 
samples and the control samples are compared and standardized such that the median 
point within the data set is 1. The data points that appear outside the threshold lines of 
the data set represent duplications and deletions. The intensity ratio of a data point 
greater than 1.33 is identified as a duplication and less than 0.75 is a deletion. 
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The second analysis occurs as a regression plot method that shows the square root 
of peak intensity deviations of the patient samples compared with the control samples. 
The software forms a best tit line and removes a specific number of outliers from the data 
and forms a new regression line. This is repeated until the regression line has reached a 
confidence of greater than 99.0% to show that the outlier alleles are truly duplication and 
deletions. The removed points are placed back into the plot as either outliers or plotted 
on the regression line. Rearrangement mutations are detected as changes in the ratio of 
peak intensities from signal amplified across the exons of the gene. 
CHAPTER IV 
RESULTS 
Sixty-four deleterious mutations and 38 genetic variants of uncertain significance 
were identified by direct sequencing and Southern blot analysis of MLH] and MSH2 in 
the original 406 specimens, showing an overall total mutation prevalence of 89%. Of the 
89%), 25%) of these mutations were rearrangelnents in MLH] and MSH2 identitied by 
Southern Blot analysis. Seventeen MLII] mutations and 31 MSH2 mutations were 
detected along with 27 genetic variants of uncertain significance in MSH] and 11 in 
MSH2. Three rearrangements were detected in MLH] and 13 rearrangements were 
detected in A1SH2 (Table 3 and Table 4). 
MSH6 Results 
Sequencing results identified six protein truncating mutations showing an overall 
J,;ISH6 mutation prevalence of 11 % (limited by mutation detection by direct DNA 
sequencing). The six deleterious mutations were distributed along the coding sequence 
of the gene. Three of the mutations, 2150de1TCAG, RI0689X, 3859de1CAAG, were 
previously characterized (Kolodner et aL 1999, Plaschke et al. 2002, Goodfellow et al. 
2003) and the remaining three appeared to be novel mutations, Q4X, 1816insA, 
2230insG (Table 5). Four of the six mutations, Q4X, 2230insG, R 1 0689X, 
3859deiCAAG were identified in patients that were diagnosed with endometrial cancer. 
Table 3 
























Summary and Prevalence of All Mutations 
MUll/ Tested iilSH6 
Paticn Relative Patien Relative Group MSH2 mutation for mutation 
Group t FC EC tCRC eRC totals count :HSI16 
+ 54 17 26.6 30 4 66.7 
:2 + 44 10 15.6 32 
3 + + 169 23 35.9 105 16.7 
4 + 47 6 9.4 40 \6.7 
5 + 61 3 4.7 49 
6 31 5 7.8 23 
The summary of all mutations detected in MLH1, MSH2, and A1SH6 and the prevalence 
of these mutations in groups 1-6. Groups 1-6 are based on cancer frequency reported 




Deleterious Mutations and Variants of Unknown 
Significance in MSH6 Identified by Sequencing 
Mutation Severity Exon 
10C>T (Q4X) Deleterious 
1816insA Deleterious 4 
2150delTCAG 1 Deleterious 4 
2230insG Deleterious 4 
3202 C>T (RI068X) 2 Deleterious 5 
3959delCAAG 3 Deleterious 9 
IVS3-7C>A Unknown 4 
663A>C (E221D) Unknown 4 
866GC>AA (G289E)* Unknown 4 
1106C>T (T369I) Unknown 4 
1856A>C (E619D) 4 Unknown 4 
2025G>C (E675D) Unknown 4 
2057G>A (G686D) Unknown 4 
3911G>A (R1304K) Unknown 9 
The six protein truncating nlutations along with 8 nlissense variants of uncertain clinical 
importance were identified in M)H6 by direct sequencing. Six of the mutations are 
deleterious and 4 of the 12 mutations were previously identified in other studies as noted 
(1). Kolodner et al. 1999 (2). Plaschke et al. 2002 (3). Goodfellow et al. 2003 (4). 
Plaschke et al. 2004. Numeric designation corresponds to transcript location based on 
GenBank BC004246, initiated from first adenine of the start codon. Amino acid change 
shown in parentheses. All mutations and variants observed once each. * Assumes 
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Figure 8. Summary of Sequencing Electropherograms of the Six Protein Truncating 
MSH6 Mutations Identified. The arrow indicates the location of each mutation; Q4X 
resides in ex on 1; 1816insA, 2150delTCAG and 2230insG reside in exon 4; R 1 068X 
resides in exon 5; 3959deiCAAG resides in ex on 9 (Hendrickson et al 2005). 
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The increased frequency of MSH6 lTIutations in patients diagnosed with 
endometrial cancer is demonstrated by other studies suggesting a connection of AISH6 
mutations with this cancer type. A statistical analysis to verify an increased association 
of endometrial cancer with MSIJ6 compared with MLH1IA-iSH2 mutation carriers showed 
that the results are suggestive, but not significant in this study (Fisher's exact test, 
p=O.062). Additionally, eight variants of unknown clinical significance were found, one 
of which was previously identified (Plaschke et al. 2004). There were no rearrangement 
mutations detected in MSH6 by MLPA analysis. Only one sample remained unresolved 
for MSH6 rearrangement mutations due to uninterpretable results. Due to the 
requirements for making the samples anonymous, additional information such as age of 
onset, cancer type and exact number of affected fan1ily members were lTIade unavailable. 
P MS2 Deletion 
The deletion of the entire P MS2 gene was identified by MLPA in a patient 
diagnosed with colorectal cancer, has a family history of colorectal cancer, but no history 
of endometrial cancer (Figure 9). With the exception of exons 13- 15, the data from this 
sample appeared consistent 'Nith a whole gene deletion mutation. This finding was 
repeated by MLP A to confirm the deletion of exons 1-15 in this sample. From the 
MLPA analysis, exons 13-15 of the PMS2 gene appeared deleted or duplicated in 
numerous patient samples. It was apparent that these probes were hybridizing to 
pseudogenes homologous to exons 13-15 of the PAfS2 gene. These results were excluded 
due to the high variability of these probes. Exons 1-12 had an average coefficient of 
variability (CV) of 6.50/0 (maximum CV=9.30/0), not including the deletion sample, while 
exons 13-15 had CV values of 28.4%, 22.90/0 and 36.60/0. 
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Figure 9. MLPA Allele-Ratio Graph Showing the Deletion of the PMS2 Gene. Data 
points below the threshold line, having an intensity allele ratio of less than 0.75, represent 
a deletion. Analysis of results was completed using cOtnmercial software (GeneMarker, 
SoftGenetics) and a synthetic population derived control. 
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The deletion of the P MS2 gene in this sample set was an additional finding in this 
study. Germline mutations in PMS2 have been reported as a rare cause ofHNPCC. Only 
six germline mutations (Nakagawa et al. 2004) and four rearrangements (van der klift 
2005) are identified in PMS2. This finding shows that the rate of PMS2 mutations is still 
unknown at this point due to testing difficulties imposed by the pseudogenes. More 
research is needed since little is known about the role of P MS2 in HNPCC. 
CHAPTER V 
CONCLUSION 
An accurate prevalence of MSH6 mutations in HNPCC can't be reported since 
results vary significantly between studies due to patient selection by researchers and 
stringent cancer type ascertainment combined with founder mutations. Plaschke et a1. 
reinforces the limitations of the classical criteria for AfSH6 detection in HNPCC 
individuals, which reported that two-thirds of families calTying AfSH6 mutations would 
have not been detected by using the Amsterdam criteria. Several studies reported that 
MSH6 mutations are more prevalent in kindreds that don~t fulfill the Amsterdam or 
Bethesda criteria (Wijnen et a1. 2003, Plaschke et a1. 2004). These data also suggest that 
families selected by the Amsterdam or Bethesda criteria for HNPCC testing appear to 
select against patients that would benefit from MSH6 testing. Because the 279 specimens 
were made tully anonymous. the remaining patient information did not permit the 
samples to be evaluated by clinically accepted standards, such as the Amsterdam or 
Bethesda criteria. This study cannot confirm that these criteria select against M';H6 
mutations in these patients. 
In these experiments, the purpose of this study was to determine the role oL\-fSH6 
mutations in North American patients receiving clinical genetic testing for HNPCC. This 
study proposed to answer several questions arising froln the role of MSH6 mutations in 
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this sample set: What are the relative prevalence of mutations in MLHJ, MSH2, and 
MSH6 in these patients and the spectrum of these mutations (point mutations verses 
rearrangements) across the three genes? Are there clinical benefits from augmenting tests 
with rearrangement detection? Do the clinical characteristics of genetic mutations vary in 
MMR genes among HNPCC individuals? 
In the clinical testing of the 406 samples, MLHI and MSH2 mutations accounted 
for 890/0 of all detectable HNPCC associated mutations in North American patients 
receiving clinical HNPCC testing. Of the 890/0, 25% of these mutations were identitied 
as rearrangement mutations in AILHI (5%) and M'lH2 (200/0) by Southern blot analysis. 
AlSH6 mutations accounted for 11 % of all HNPCC associated mutations in this sample 
set. MLPA analysis did not identify any rearrangement mutations in the MSH6 gene. 
'rhis demonstrates rearrangement mutations occur less frequently in MSH6 when 
compared to point mutations but could be due to the small sample size of this study. This 
study can confirm that rearrangement mutations in MLH I and MSH2 account for about 
250;() of all mutations in HNPCC when compared with other studies. These findings also 
confirm that the majority of MMR mutations occur in MLHI and AlSH2 and less 
frequently in MSH6 in HNPCC families. 
It has been shown that MSH6 kindreds are often distinguished by endometrial 
cancers, lower penetrance of colorectal cancer, and later age of onset when compared 
with kindreds that carry lilLlfl and MS}{2 mutations. It has been shown that 52-730/0 of 
cancers in MSH6 germline mutation carriers are endolnetrial cancers (Buttin et a1. 2004) 
with the average age of onset of 61 years of age (Kolodner et a1). In the study by Buttin 
et aI., 580/0 of MSH6 mutations were detected in patients with endometrial cancer with a 
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lower penetrance in colorectal cancer. Four out of six mutations in MSH6 were found in 
patients diagnosed with endometrial cancer. The data appear suggestive, but not 
significant as shown by a statistical analysis (Fisher's exact test, p=0.062). There was 
insufficient patient information to show if the families associated with MSH6 mutations 
displayed a later age of onset. 
By augmenting tests with rearrangement detection by MLPA, a deletion of the 
PA4S2 gene was identified in a patient diagnosed with colorectal cancer, had a family 
history of colorectal cancer, but no history of endometrial cancer. This mutation would 
not have been detected with only the incorporation of conventional methods such as 
DDGE, DHPLC, or direct sequencing for mutation detection. 
The MutLa heterodimer formed by the MLHl and PMS2 protein is a major 
component of the MMR complex (Nakagawa et al. 2004). Germline mutations in PMS2 
are rare and have been reported in only a few families with cancer (De Vos et al. 2003, 
van der Klift 2005) despite its important role in the MMR pathway. It has been shown 
that PMS2 mutated human cells display a n1utation rate equivalent to or higher than 
A1Llil mutated human cells, but reported PMS2 mutations are low (De Vos et aL 2004). 
More data needs to be obtained to understand the mechanism of \vhich P MS2 mutations 
predispose individuals to HNPCC. One possible reason for the under diagnosis of PMS2 
mutations could be the existence of pseudogenes corresponding to the first five exons, 
exon 9, and exons 11-15 of PMS2 to interfere with analysis. 
CHAPTER VI 
DISCUSSION 
According to the HNPCC database, MSli6 is the third 1110st comnl0n gene 
associated with HNPCC. MSH6 mutations account for 10%) of all mutations in HNPCC, 
which is confil111ed by this study (Kariola et a1. 2002). MSH6 mutations are linked to 
1~lmijies that display less common clinical features associated with HNPCC (Wijnen et a1. 
1999), such as a higher incidence of endometrial cancers, lower penetrance of colorectal 
cancer and a later of onset when cOl11pared with kindreds carrying MLlf 1 and MSH2 
mutations. By using the classical criteria for the selection of individuals for HNPCC 
testing, nlany individuals harboring MSl16 nlutations could be overlooked. MSH6 
Illutations require the same or nlore stringent level of survei11ance as for any other MMR 
lllutation in IINPCC kindreds (Offtt 2004), but require a broader selection criterion. 
Overall this study shows that disease causing MSH6 nlutations are rarer among 
IJNPCC {~1l11ilies when conlpared with MSH2 and MLHl 111utations. In this study, the 
prevalence of MSlf6 nlutations was detenllined in a clinical population of North 
Americans receiving HNPCC clinical testing. This study shows testing in a more 
practical clinical population of faJl1ilies that would benefit fi"0111 MS[i6 testing, since 
several studies reports MSH6 nlutations are more prevalent in kindreds that don't fulfill 
Alllsterdanl or Bethesda criteria (Wijen et a1. 2003, Plaschke et al. 2004). 
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At this time, it is not clear how MSH6 analysis should be incorporated into 
HNPCC clinical testing; therefore it is suggested that MSH6 sequence analysis should be 
done in HNPCC families when no other mutations are identified in AILH I and A1SH2 and 
in families with a history of endometrial cancer as well as colorectal cancer regardless of 
age. MSH6 analysis should also include the screening of genomic rearrangements when 
no other mutations are detected in other MMR genes. It has been shown by this study 
that mutations in MSH6 playa lesser but important role in the cause of HNPCC. Since 
MLPA has been proven to be rapid and simple, this assay could be incorporated into a 
clinical setting as an initial screening tool for mutation detection. 
It has been shown that there are clinical benefits from combining conventional 
detection with rearrangement detection by MLPA. It has increased sensitivity of 
mutation detection and can be used as a fast, simple, reliable screening tool for 
rearrangement detection. Most PCR-based methods are effective at detecting point 
Inutations, but are insensitive to detecting large gene rearrangements. Southern blot 
analysis is most commonly elnployed for the detection of genomic deletions and 
duplications, but it is time consuming and laborious, requires large amounts of DNA, and 
requires expert analysis. Screening for genomic deletions in MMR genes, especially in 
lvfSH2 and MLH1, is essential for the diagnosis ofHNPCC. Since MLPA is rapid, 
efficient, and a sinlple technique for the detection of genomic deletions in MMR genes, it 
could be incorporated into the initial screening process for MMR gene mutation analysis. 
Without the screening for genomic rearrangements in MSH2 and MLH 1, up to 300/0 of 
these nlutations could go undetected due to the incorporation of methods that are 
insensitive to genomic rearrangements. 
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Published reports regarding MSH6 mutations describe research specimens that 
were selected by various criteria that make correlations to the clinical population 
undergoing testing difficult. This is not unusual in the field of human genetics where 
initial discoveries occur in highly selected specimen sets. It is now known that the 
Amsterdanl or Bethesda criteria select against MSH6 mutations and more infornled 
decisions to develop the correct patient criteria for MSH6 testing will require additional 
clinical data for the systematic analysis of point and rearrangement mutations in UC:;}f6. 
This study could not properly display the prevalence of MSH6 rearrangements versus 
point mutations due to the snlall sanlple size of this study. More research is needed to 
determine the importance of U5}!6 rearrangements in HNPCC. Results from this study 
and other recently published studies support the conclusion that MSH6 testing is an 
important part of genetic testing for HNPCC individuals. The need to correctly identify 
all mutations in HNPCC individuals and HNPCC-like families is important since the cost 
of clinical testing is high and also to prevent unnecessary testing in unaffected 
individuals. 
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